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Summary The vast majority of studies on tumour vasculature are performed on transplanted tumours in
rodents. However, it is known that there may be differences between primary and transplanted lesions. The
purpose of this study is to test whether a specific vascular response is similar in primary tumours and in
transplanted tumours derived from them. The technique used was to give an intraperitoneal injection of
5 mgkg-l hydralazine, which is known to result in hypoxia in transplanted tumours. Changes in perfusion
were indicated by changes in metabolism, monitored using 31P Magnetic Resonance Spectroscopy. The
primary tumours were induced by local irradiation many months previously and only 4/11 (36%) of these
responded to hydralazine. One of the non responders was subsequently transplanted into isogeneic mice to
produce a tumour line which was histologically very similar to the primary. Of these 16/17 (94%) responded.
The difference is statistically significant (P = 0.001). The reasons for this difference are not known. A number
of possibilities are discussed and in the authors' opinion, the most likely cause is that it results from an
artefact of transplantation.
Tumour vasculature is thought to differ from that of normal
tissues in many respects. Angiogenic factors produced by
neoplastic cells (Folkman, 1974) stimulate the production of
vessels which are characterised by a lack of basal lamina,
smooth muscle and innervation and there is often an absence
of or very few endothelial cells. Tumour vessels tend to be
long and tortuous with frequent A-V shunts. The vascular
pattern is frequently chaotic and blood flow is highly
heterogenous, with regions of high flow and also regions of
very low or even zero flow. The vessels tend to be leaky,
causing increased interstitial pressure and oedema, which is
exacerbated by poor or absent lymph drainage. On the
arterial side, microvascular pressure is similar in tumour and
in normal tissue, whereas the more numerous tumour venular
vessels are at a significantly lower pressure than those in
normal tissue. There is a tendency for platelet aggregation
and erythrocyte rigidity (see reviews by Jain & Ward-Hartley,
1984; Reinhold & Endrich, 1986).
Tumours tend to outgrow their nutrient supply and so
develop necrotic centres as well as microscopic regions of
hypoxia when cells become too distant from the nearest
blood supply to be properly oxygenated (Thomlinson &
Gray, 1955). In addition, the high interstitial pressure
coupled with low intravascular pressure leads to haemostasis
and frequent flow reversal. Chaplin et al. (1987) demon-
strated clearly the transient nature of blood flow in some
tumour vessels with changes from adequate perfusion to zero
flow in times of the order of 20 min.
Since tumour vasculature plays a crucial role in all forms
of cancer therapy there has been a long standing interest in
its manipulation for therapeutic gain (Cater et al., 1962;
Kruuv et al., 1967). In particular, there have been major
efforts to improve tumour oxygenation and blood flow in
order to increase both radiation sensitivity and the penetra-
tion of chemotherapeutic drugs. More recently the potential
advantages of decreasing tumour perfusion thus causing a
decrease in oxygenation and pH have been realised. These
changes could potentiate the action of certain drugs, reduce
the rate of removal of chemotherapeutic agents from tumour
and increase the effectiveness of hyperthermia (Brown, 1987;
Chaplin & Acker, 1987; Stratford et al., 1987; Horsman et
al., 1989).
However, virtually all of these conclusions are derived
from studies performed on transplanted animal tumours. It is
known that vascular architecture and hence its response not
only varies among tumour types, but may differ between a
spontaneous tumour and its' transplants (McCredie et al.,
1971; Falk, 1980, 1982; Jain, 1988). These differences may
relate to the rate of vessel development. For example, more
rapidly developing vasculature appears to be more fragile
(Hill et al., 1989).
The aim of the present study was to further our under-
standing of the extent to which transplanted tumours may or
may not be similar to that of the original primary lesion.
This has been done by comparing the responses of primary
tumours with that of their transplants to perturbation by
administration of the vasodilator hydralazine.
It is well known that in transplanted tumours hydralazine
causes a substantial reduction in tumour blood flow (Brown,
1987; Chaplin & Acker, 1987; Stratford et al., 1989). Also
magnetic resonance spectroscopy has been used to demon-
strate a reduction in perfusion in transplanted mouse
tumours following hydralazine administration as indicated by
a reduction in both PCr/Pi and NTP/Pi ratios and a shift to
lower pH (Okunieff et al., 1988; Bhujwalla et al., 1990a).
Blood flow, assessed by hydrogen clearance is also greatly
reduced (Bhujwalla et al., 1990b) whilst there is no detectable
change in these parameters in normal muscle.
We have measured. the changes in NMR parameters fol-
lowing hydralazine given to mice bearing tumours which
were derived by local irradiation between 43 and 109 weeks
earlier, the average being 80 weeks. Similar studies were
performed on transplanted tumours derived from these
primaries.
Methods
Tumours
Primary skin tumours were induced in the flank and lower
back of SAS/4 and CD1 outbred and CBA and C57BI inbred
mice by 25-10OGy thulium-170 beta irradiation using the
method described by Williams et al. (1986). The latent period
of the tumours varied from 43-109 weeks, the majority being
of dermal origin, classified as malignant fibrous histio-
cytomas or fibrosarcomas. They had volume doubling times
of 2-12 weeks.
Following spectroscopy, one of the primary tumours in a
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CBA inbred mouse (which was a 'non responder', see below)
was excised and 1-2 mm3 pieces were transplanted sub-
cutaneously into the flanks of isogeneic mice. In this way a
transplanted tumour line was derived. Studies were per-
formed on 1st, 2nd and 3rd generation transplants. Details of
volume doubling times, volumes at time of treatment and
latent period are given for both primary and transplanted
tumours in Table I.
Tumour were fixed in bouin's and 10% buffered neutral
formol saline and stained with Ehrlich's haematoxylin and
eosin.
Magnetic Resonance Spectroscopy
31P MRS was performed on a 1.89 T Oxford Research
Systems TMR-32 spectrometer. Mice were anaesthetised and
placed on a flask containing circulating, heated water in
order to maintain their body temperature. The mice were
carefully positioned within the bore of the magnet so that the
tumour faced upwards; onto it was placed an 11 mm
diameter, two turn surface coil, lightly touching the tumour.
31P data were accumulated in blocks of 10 or 20 min (from
the sum of 300 or 600 free induction decays) with a pulse
length of 10 s and a pulse repetition time of 2 s. All data
were therefore averages over the scanning period. Mice were
anaesthetised with sodium pentobarbitone (55 mg kg-') given
intraperitoneally to restrain them within the magnet. It was
occasionally necessary to 'top-up' the anaesthetic dose and
this was done via the same intraperitoneal catheter. Follow-
ing a baseline spectrum, hydralazine (5 mg kg-') was injected
via the intraperitoneal catheter, without disturbing the posi-
tion of the mice in the magnet. Further spectra were then
accumulated for up to 40 min. Data processing involved
exponential line broadening and spectral deconvolution. Fur-
ther details could be found elsewhere (Tozer & Morris, 1989).
31p parameters are expressed as the ratios of Pi peak to the
total phosphate signal area (Pi/lp), and as PNTP/Pi.
Results
The response of the transplanted tumours to hydralazine was
similar to that published elsewhere (Bhujwalla et al., 1990a).
The majority showed a substantial increase in Pi/Ep and a
corresponding decrease in PNTP/Pi. Using the ratio PNTP/Pi,
a positive response was defined as a decrease in ,NTP/Pi by
greater than 15%. A smaller change was probably not statis-
tically significant. 16/17 transplanted tumours were re-
sponders to hydralazine. In contrast, only 4/11 primary
tumours were responders. These results are shown in Table
II. These ratios are significantly different from each other
(P = 0.001). It is important to note that the transplanted
tumours were all derived from a primary which did not
respond.
We examined the data for a relationship between PNTP/Pi
and either volume at the time of experiment or tumour
doubling time. There was no obvious correlation in either
case (Figures 1 and 2).
The magnitude of the response for those tumours which
were defined as responders is shown in Table III. The results
for both PNTP/Pi and Pi/Ep are shown and it is clear that
for the responders, the magnitude of response is similar for
the primary and transplanted tumours. Bhujwalla et al.
(1990b) have shown changes in PNTP/Pi to be a sensitive
indicator of changes in tumour blood flow. For example, a
reduction in blood flow from 15 to approximately 10 ml
100 gm-I min' caused a halving of the ratio, and a further
reduction to 5 ml 100 gm' min-' abolishes the PNTP/Pi
peak altogether.
Discussion
Although the study was small, comprising 11 primary and 17
transplanted tumours, there can be no doubt that the two
types respond differently to hydralazine, as shown in Table
II.
Nearly all the transplanted tumours exhibited changes in
MRS parameters in response to the vasodilator, consistent
with a reduction in blood flow. Similar or related results have
been demonstrated elsewhere many times using transplanted
tumours (e.g. Babbs et al., 1982; Bhujwalla et al., 1990a and
b; Brown, 1987; Chaplin & Acker, 1987; Okunieff et al.,
1988; Stratford et al., 1987; Horsman et al., 1989). In marked
contrast the majority of the primary tumours in the present
study did not respond to the drug. Those tumours that did
respond, however, did so to the same extent as the trans-
planted tumours (Table III).
There are a number of factors which should be considered
as possibly influencing the result.
(1) The primary tumours were radiation induced. A long
term effect of irradiation might be to reduce the potential of
the tumour vasculature to react to external stimuli. Two
mechanisms have been proposed for the action of hydrala-
zine in causing reduced tumour blood flow. One is that the
reduction of systemic blood pressure results in vascular col-
lapse of the tumour vessels and the second is that in contrast
to the normal tissues the tumour vessels do not dilate, caus-
ing a redistribution of total cardiac output from tumour to
normal tissues. In neither case does it seem likely that
radiation-compromised vessels would prevent these changes.
In addition irradiation took place an average of 20 months
earlier when much of the effect of irradiation will have
repaired. We feel that it is unlikely that the lack of response
of the primary tumours could be the result of their having
been radiation-induced. In addition, preliminary studies with
NMU-induced mammary carcinoma in rats appears to con-
firm that these primary tumours do not respond to hydrala-
zine. Of three tumours studied so far, none showed any
response to intravenous administration of a dose of
I mg kg-' hydralazine, despite a corresponding reduction of
45% in blood pressure.
(2) The effect may depend on the histology of the tumour.
Table IV shows that the primaries were of three types,
fibromas, malignant fibrous histiocytomas and fibrosarcomas.
In general, the fibrosarcomas responded in a similar way to
the transplanted tumours. The more malignant MFH did not
respond and neither did the non-malignant fibromas. It is
important to note that the responding transplanted tumours
were all derived from one of the responding MFHs and the
histology of the primary and transplanted tumours was quite
comparable as seen in Figure 3. Clearly some primary
Table I Growth characteristics of primary and transplanted tumours
Primary Transplanted
Responders Non-responders Responders Non-responders
Doubling time 18.3 37.0 9.7 11.0
(days) (10-35) (10-84) (4-17)
Volume at 1955 795 1693 2000
treatment (mm) (420-3200) (130-1900) (300-3800)
Interval between irradiation or 92 75 5.4 8
transplantation and spectroscopy (80-101) (43-109) (2-11)
(weeks)
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tumour types do respond, but response is not obviously
related to degree of malignancy. The transplanted tumours
were subcutaneous whereas the primary tumours were mainly
of dermal origin. However, it was seen on excision that
primary tumours were fed by at least two large vessels arising
from underlying muscle and tissue, similar to the majority of
transplanted tumours.
Table II Response of tumours to hydralazine, measured by change
in the ratio 0NTP/Pi. A change by greater than 15% is defined as a
positive response
Type of twnour Responding Non-responding
Primary (4/11) 36% (7/11) 64%
Transplanted (16/17) 94% (1/17) 6%
Table IV Reaction of tumours to hydralazine as a function of their
histology
No. of Reaction grade
Histology tumours - 0 + + +
Fibroma 3 2 1 0 0
Malignant fibrous 4 0 3* 1 0
histiocytoma
Fibrosarcoma 4 1** 0** 0 3
Reaction grade is defined in terms of a change in PNTP/Pi, such
that: - is an increase. Ois no significant change (± 15%). + is a
reduction of between 15 and 50%. + + is a reduction of more than
50%. Transplanted tumours derived from a non-responding MFH.
**Poorly differentiated fibrosarcoma: might be classified as MFH.
The primary and transplanted tumours responded differently
P = 0.001. Note: The transplanted tumour line was derived from a
non-responding primary.
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Figure 1 Changes in PNTP/Pi as a function of volume of
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Figure 3a Histological section of a primary malignant fibrous
histiocytoma. 5 fs, H and E stained. Magnification x 40, b, Histo-
logical section of a transplanted malignant fibrous and histio-
cytoma, derived from the primary pictured in a. 51,
H and E stained. Magnification x 40.
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0 (3) Volume of tumour at time of study. It is seen in Figure 1 1.4 and Table I that for the tumours which responded to hy-
dralazine, both the primaries and transplanted, the range and
o.o- * averages of tumour volume at the time of study were
40 60 80 100 comparable. The volume of the single non-responding trans- 0 20 40 60 80 100 planted tumour was close to the average. The non-
Tumour doubling time responding primary tumours were on average smaller than
Changes in .NTPP as afunctionoftumourdoubl the responders, however, they covered a similar range of
Changes in NTP P avolumes. It
is unlikely that tumour volume at the time of Lch point represents data from one animal. El Primary; study was a major influencing factor.
isplanted. (4) Tumour growth rate. The transplanted tumours all
grew faster than the primaries. The non-responding were
more slowly growing than the responding primaries, but the
Table III Magnitude of response average was strongly influenced by two very slowly growing
lesions. The range ofgrowth rates was fairly similar (Figure 2
Transplanted Primary and Table I).
NTP/Pi 0.46 0.04 0.48 0.08 (5) The primary tumours took an average of 80 weeks
Ii/Lp 1.79 0.20 1.77± 0.30 from the time of irradiation to study. The interval was
are mean ± s.e.m. for four responding primary and 16 similar and certainly not significantly different between re-
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took an average of 5-6 weeks from the time of transplanta-
tion, but the single non-responder fell within the range of
times for the responders (Table I).
(6) The primaries were growing in an inbred strain of
mouse and were transplanted into isogeneic animals. Mice
were 10-12 weeks old when irradiated to induce tumours,
which developed more than 1 year later. In contrast, mice
were 10-20 weeks old for transplantation, tumours develop-
ing in a few weeks. Hence, the mice bearing primary tumours
were much older when they were studied. It is possible that
the vasculature in older animals respond differently to that in
young mice, but there is no evidence to explain the results on
this basis.
(7) Dose. The dose of hydralazine of 5 mg kg-' used in
this study is extremely high. It is known to produce hypoxia
in virtually all the transplanted tumour models that have
been studied. This dose results in 40-50% reduction in mean
arterial blood pressure (Field & Burney, unpublished). It is
inconceivable that the dose used is in the region of a
threshold.
(8) Effect of transplantation. The vasculature which
develops in a transplanted tumour is often different from that
in primaries (Falk, 1980, 1982; Jain, 1988). The fact that the
primary MFH tumours did not become hypoxic following
hydralazine injection whereas 16/17 of the transplanted
MFHs did might simply be due to an 'artefact' of transplan-
tation. In the authors opinion this is the most likely explana-
tion.
Conclusion
On the basis of the evidence presented, it is plausible that the
difference in response observed between the primary and
transplanted tumours results from the procedure of trans-
plantation itself. However, this study does not prove une-
quivocally that the response to hydralazine is an artefact of
transplantation and various further studies are in progress to
examine the possibility that confounding factors might have
influenced the results. Nevertheless, we believe that it would
be prudent to assume that studies of the vasculature in
transplanted tumours can not necessarily be extrapolated to
man unless supporting evidence is provided.
We gratefully acknowledge the contribution from Dr J.M. Brown,
who suggested that we try to study the response of transplanted
tumours derived from a non-responding primary.
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